American Liver Foundation

World-renowned Chefs Gather to Raise Awareness and Funds for Liver Disease

Retrieved on: 
Wednesday, April 3, 2024
Local, Education, Wrigley Mansion, ALF, American Liver Foundation, Research, Iron Chef, Iron Chef America, Restaurant, Heart, Table, Liver disease

NEW YORK, April 3, 2024 /PRNewswire/ -- The American Liver Foundation (ALF) has teamed up with world-renowned culinary expert Chef Christopher Gross and Celebrity Chef Mark Tarbell from Iron Chef for FLAVORS, a national culinary event to be held in Phoenix, Arizona on May 22, 2024.

Key Points: 
  • ALF and world-renowned culinary expert Chef Christopher Gross team up for FLAVORS, a national culinary event on May 22.
  • "ALF is delighted for the return of FLAVORS with our founder, Chef Christopher," said Lorraine Stiehl, Chief Executive Officer, American Liver Foundation.
  • "The generosity of these chefs and those philanthropists attending help us continue to provide life-saving resources, support, research and education for the nearly 100 million of Americans affected by liver disease."
  • Chef Christopher will be joined by seven other local chefs, including Mark Tarbell, winner of 2007 "Iron Chef America".

American Liver Foundation Celebrates Donate Life Month with New Patient Resources, Programs and Support

Retrieved on: 
Monday, April 1, 2024
American Liver Foundation, Journey, Celebration, Liver disease, Environment, Caregiver, Patient, Social media, News, Liver transplantation, MD, ALF, North Shore University Hospital, Liver, Partner, Fatigue, Sadness, Dentistry

April is Donate Life Month and American Liver Foundation (ALF) has new patient resources, programs and support available to all liver transplant patients and the caregivers supporting them.

Key Points: 
  • April is Donate Life Month and American Liver Foundation (ALF) has new patient resources, programs and support available to all liver transplant patients and the caregivers supporting them.
  • "An informed patient is critically important to making the best decisions about care and ensuring the most favorable outcomes," said Lorraine Stiehl, Chief Executive Officer, American Liver Foundation and caregiver to a transplant recipient.
  • Liver patients, families and loved ones are invited to celebrate the gift of life and the importance of liver transplantation.
  • Throughout Donate Life Month ALF encourages patients, caregivers and organ donors to be part of the national conversation!

American Liver Foundation Statement on FDA Approval of Resmetirom

Retrieved on: 
Thursday, March 14, 2024
HCC, Liver failure, American Liver Foundation, Fatty liver disease, Liver disease, Disease, Caregiver, Risk, Cirrhosis, Inflammation, Chairperson, Patient, Life, Liver transplantation, Hope, Doctor of Philosophy, MASH, MD, ALF, Pharmacotherapy, Fibrosis, NASH, Hepatology, Hepatocellular carcinoma, NAFLD, FDA, Liver, Food, Pharmaceutical industry

FAIRFIELD, N.J., March 14, 2024 /PRNewswire/ -- Today, the Food and Drug Administration (FDA) granted accelerated approval of a first of its kind drug therapy, resmetirom, for the treatment of nonalcoholic steatohepatitis (NASH) in patients who have progressed to fibrosis. NASH, now called metabolic dysfunction-associated steatohepatitis or MASH, is a dangerously progressive form of nonalcoholic fatty liver disease* (NAFLD) and causes inflammation in the liver and liver damage.

Key Points: 
  • NASH, now called metabolic dysfunction-associated steatohepatitis or MASH, is a dangerously progressive form of nonalcoholic fatty liver disease * (NAFLD) and causes inflammation in the liver and liver damage.
  • "American Liver Foundation applauds the FDA approval of the groundbreaking new drug therapy treatment, resmetirom, for patients with NASH who have progressed to fibrosis," said Lorraine Stiehl , Chief Executive Officer, American Liver Foundation.
  • American Liver Foundation offers many free resources to patients and families affected by liver disease.
  • *Note: The nomenclature for NAFLD and NASH recently changed to metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) respectively.

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Retrieved on: 
Wednesday, February 28, 2024
Oncology, Professional Services, Health, Finance, General Health, Pharmaceutical, Biotechnology, CANF, Non-alcoholic fatty liver disease, Psoriasis, CMS, Liver disease, ALT, Fatty liver disease, Patent, Use, Inflammation, CKD, Human, Partner, Patient, IP, NASH, Phase, American Liver Foundation, Pharmaceutical industry

(NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application titled “An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation”.

Key Points: 
  • (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application titled “An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation”.
  • This invention addresses the use of Namodenoson for the reduction of liver fat in patients with NASH a clinical indication that is being developed by Can-Fite.
  • The Company also has a distribution agreement in Canada for its anti-inflammatory drug, Piclidenoson, for the treatment of psoriasis.
  • “This additional patent in Canada for fatty liver disease adds to our growing IP estate for this high-value indication of the Namodenoson drug candidate.

American Liver Foundation Announces Recipients of 2023 Liver Research Awards

Retrieved on: 
Thursday, January 25, 2024
Cirrhosis, Research, Fibrosis, ALF, COVID, Genetics, Liver cancer, Fatty liver disease, Disease, Patient, Liver, Doctor of Philosophy, Biomarker, American Liver Foundation, Lipid metabolism, Liver disease, Dietary supplement

FAIRFIELD, N.J., Jan. 25, 2024 /PRNewswire/ -- Today, the American Liver Foundation (ALF) announced ten new liver research awards that will fund early career scientists working in basic and translational liver disease research. Three researchers will receive a Liver Scholar Award, and seven will receive a Postdoctoral Research Fellowship Award to help advance research in liver biology and disease.

Key Points: 
  • Research topics include fatty liver disease, rare and pediatric liver disease, liver cancer, cirrhosis and more
    FAIRFIELD, N.J., Jan. 25, 2024 /PRNewswire/ -- Today, the American Liver Foundation (ALF) announced ten new liver research awards that will fund early career scientists working in basic and translational liver disease research.
  • Three researchers will receive a Liver Scholar Award , and seven will receive a Postdoctoral Research Fellowship Award to help advance research in liver biology and disease.
  • ALF announces $850,000 in awards to fund early career scientists in basic and translational liver disease research.
  • The 2023 research awards, totaling $850,000 over a three-year period, include research topics such as lipid metabolism, biomarkers, genetics, microbiome immune response, and liver environment, and address important questions in the pathophysiology of fatty liver disease (now called steatotic liver disease), pediatric liver disease , rare liver disease , liver cancer , fibrosis / cirrhosis , and alcohol-associated liver disease .

Non-alcoholic steatohepatitis (NASH) real-world evidence innovation further extends Verantos' lead in artificial intelligence for cardiometabolic conditions

Retrieved on: 
Monday, November 13, 2023
RWE, Hepatology, PALO, NAFLD, Natural language processing, Organization, Prevalence, AASLD, DSM-IV codes, Patient, RWD, American Liver Foundation, Intelligence, Obesity, Non-alcoholic fatty liver disease, Chronic liver disease, NASH, Medical device

PALO ALTO, Calif., Nov. 13, 2023 /PRNewswire/ -- Verantos, the global leader in high-validity real-world evidence at scale, today announced the presentation of an abstract on the use of artificial intelligence in cardiometabolic conditions. The technology enables researchers to gather high-quality real-world data on NASH, non-alcoholic fatty liver disease (NAFLD), and related conditions.

Key Points: 
  • PALO ALTO, Calif., Nov. 13, 2023 /PRNewswire/ -- Verantos , the global leader in high-validity real-world evidence at scale, today announced the presentation of an abstract on the use of artificial intelligence in cardiometabolic conditions.
  • The technology enables researchers to gather high-quality real-world data on NASH, non-alcoholic fatty liver disease (NAFLD), and related conditions.
  • "Verantos' advances in artificial intelligence afford life sciences organizations unprecedented real-world insights into metabolic diseases," said Dan Riskin, M.D., CEO of Verantos.
  • The number of cases is growing with the increasing prevalence of obesity and type 2 diabetes.

American Liver Foundation Hosts the 32nd Annual Irwin M. Arias Symposium

Retrieved on: 
Thursday, November 2, 2023
Massachusetts General Hospital, Science, ALF, MACP, MIT, ISCB Senior Scientist Award, National Institutes of Health, Gastroenterology, Physician, Danny Howells, American Liver Foundation, Liver, MD, Doctor of Philosophy, Liver disease, Research, Engineering, Disease, Biology, Biomedical engineering, NIH, Nobel Prize, Hepatology, Collection, Nobel Prize in Physiology or Medicine, Patient, Diagnosis, Hospital, Bangladesh Technical Education Board, Wolfram Goessling, Pharmaceutical industry, Nursing, Physiology, Medicine

FAIRFIELD, N.J., Nov. 2, 2023 /PRNewswire/ -- The American Liver Foundation is pleased to host its 32nd annual Irwin M. Arias Symposium, Bridging Basic Science and Liver Disease, on November 16th from 9AM to 5PM ET. This one-day virtual and in-person program brings together hundreds of leading biomedical scientists and physicians from across the globe and is designed to bridge the remarkable advances in basic biology and engineering with the understanding of liver diseases and their treatment.

Key Points: 
  • Virtual and in-person event, Bridging Basic Science and Liver Disease, brings together hundreds of leading biomedical scientists and physicians from across the globe
    FAIRFIELD, N.J., Nov. 2, 2023 /PRNewswire/ -- The American Liver Foundation is pleased to host its 32nd annual Irwin M. Arias Symposium, Bridging Basic Science and Liver Disease , on November 16th from 9AM to 5PM ET.
  • ALF hosts Arias Symposium, Bridging Basic Science and Liver Disease, Nov. 16th 9AM-5PM ET.
  • alfevents.org/ariassymposium
    "ALF's annual Arias Symposium has become a go-to event for scientists interested in exploring the connections between research conducted in the lab and treatments delivered in the clinic," said Lorraine Stiehl, CEO, American Liver Foundation.
  • "ALF's Arias Symposium has been a model in addressing this challenge with respect to the liver.

American Liver Foundation Hosts Free Liver Cancer Conference for Patients and Families

Retrieved on: 
Wednesday, October 18, 2023
Knowledge, ALF, DO, Genomics, AstraZeneca, NCI, University of Florida Health, MPH, University of Wisconsin–Madison, Health, Education, MD, California Pacific Medical Center, Conference, MBA, Research, American Liver Foundation, Yale University, Parul, Liver cancer, Doctor of Public Health, Caregiver, Environmental epidemiology, Rush University Medical Center, National Cancer Institute, University, NIH, Mindfulness, Memorial Sloan Kettering Cancer Center, Patient, Houston Methodist Hospital, Bangladesh Technical Education Board, MS, Dietary supplement, Pharmaceutical industry, Eisai

FAIRFIELD, N.J., Oct. 18, 2023 /PRNewswire/ -- October is Liver Cancer Awareness Month and American Liver Foundation is pleased to host The Educated Patient: A Liver Cancer Conference Presented on October 21stf from 11AM to 2PM ET. Now in its fourth year, this one-day virtual education program is created especially for liver cancer patients, family members or caregivers who can register for free. The conference offers presentations, workshops and opportunities for engagement with leading medical experts, researchers and others knowledgeable about the issues most relevant to those dealing with liver cancer.

Key Points: 
  • The one-day virtual event brings together patients, caregivers, leading medical experts and researchers
    FAIRFIELD, N.J., Oct. 18, 2023 /PRNewswire/ -- October is Liver Cancer Awareness Month and American Liver Foundation is pleased to host The Educated Patient: A Liver Cancer Conference Presented on October 21stf from 11AM to 2PM ET.
  • Now in its fourth year, this one-day virtual education program is created especially for liver cancer patients, family members or caregivers who can register for free .
  • ALF's free virtual Liver Cancer Conference is October 21st.
  • She added, "We hope that this year's conference will provide patients and their families with new knowledge, resources, and support."

Marathon Runners Take to the Windy City to Raise Awareness of Liver Disease

Retrieved on: 
Wednesday, October 4, 2023
Chicago Marathon, Travel, University, ALF, University of Michigan, Life, Liver disease, Grant Park, American Liver Foundation, Primary sclerosing cholangitis, Research, Liver cancer, MHS, Running, MD, Patient, Physician, Non-alcoholic fatty liver disease, Gambat Liver Transplant Center, Bank, Team, Dietary supplement

FAIRFIELD, N.J., Oct. 4, 2023 /PRNewswire/ -- The American Liver Foundation (ALF) is proud to once again be a member of the Bank of America Chicago Marathon Official Charity Program for the 2023 race, which takes place on Sunday, October 8, 2023, in iconic Grant Park.

Key Points: 
  • "There are nearly 100 million people in the U.S. affected by liver disease, and most aren't aware they even have it.
  • That's why we are so honored that these runners have chosen to join us to help raise awareness and funds to combat liver disease."
  • The American Liver Foundation's Bank of America Chicago Marathon team has already met their fundraising goal and has since increased it.
  • The American Liver Foundation team is made up of runners with varying levels of experience from novice to advanced, most of whom have a connection to liver disease.

October is National Liver Awareness Month, Are You at Risk?

Retrieved on: 
Friday, September 29, 2023
Learning, AstraZeneca, Fatty liver disease, Partnership, Obesity, ALF, Diet, NASH, Genetics, Liver disease, Liver cancer, Non-alcoholic fatty liver disease, American Liver Foundation, Research, Inflammation, Education, Federally Qualified Health Center, Patient, Cooking, Risk, Liver, Knowledge, NAFLD, BMI, Hispanic, Liver failure, Conference, Caregiver, Dietary supplement

FAIRFIELD, N.J., Sept. 29, 2023 /PRNewswire/ -- October is National Liver Awareness Month and the American Liver Foundation is encouraging everyone to find out if they are at risk for fatty liver disease through its public awareness campaign, Think Liver Think Life™. Fatty liver disease affects an estimated 80-100 million Americans and is present in up to 75% of overweight people and in more than 90% of people with severe obesity. Through a simple liver health quiz, available at ThinkLiverThinkLife.org in both English and in Spanish, anyone can find out if they're at risk and learn what to do next.

Key Points: 
  • FAIRFIELD, N.J., Sept. 29, 2023 /PRNewswire/ -- October is National Liver Awareness Month and the American Liver Foundation is encouraging everyone to find out if they are at risk for fatty liver disease through its public awareness campaign, Think Liver Think Life™.
  • "This October, we encourage everyone to do something positive for your liver by taking our free liver health quiz ," said Lorraine Stiehl, Chief Executive Officer, American Liver Foundation.
  • The Think Liver Think Life national public health campaign aims to ensure every American understands their risk for liver disease, receives the appropriate diagnostic testing and care coordination and feels well-informed and supported throughout their liver journey.
  • Nonalcoholic steatohepatitis (NASH) is a form of NAFLD causing inflammation of the liver and liver damage, which can lead to liver failure.